Open House Drug Discount Agreements Dimethylfumarate, ATC L04AX07
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Dimethylfumarat, ATC L04AX07
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No estimated value or maximum framework value is provided. The financial potential of the agreement cannot be assessed.
Agreements automatically expire if a standard discount contract for Dimethylfumarate is concluded at federal or state l...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2028
- Pharmaceutical companies can enter into non-exclusive discount agreements for Dimethylfumarate (ATC L04AX07) with AOK Bayern.
- Agreements are identical for all participants, not individually negotiated.
Show full summary
This is an open-house model (non-exclusive) for pharmaceutical companies to enter into identical discount agreements for the active substance Dimethylfumarate (ATC L04AX07) with AOK Bayern. Contracts run from 01.06.2026 to 31.05.2028 and can be terminated monthly. Eligibility requires a signed declaration of reliability. No estimated value is provided. The procedure is not subject to standard procurement law.
Risks
No estimated value or maximum framework value is provided. The financial potential of the agreement cannot be assessed.
Agreements automatically expire if a standard discount contract for Dimethylfumarate is concluded at federal or state l...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company.
Administrative
- Submit signed declaration of reliability.
- Submit signed contract and annex listing pharmaceutical products.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open House Drug Discount Agreements Dimethylfumarate, ATC L04AX07
Non-exclusive discount agreements for Dimethylfumarate. All pharmaceutical companies meeting eligibility can participate. Contracts identical, not individually negotiated. Early start 01.06.2026, end 31.05.2028. Monthly entry possible until 03.04.2028.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Dimethylfumarat, ATC L04AX07
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 14 Apr 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 254783-2026
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No estimated value or maximum framework value is provided. The financial potential of the agreement cannot be assessed.
Agreements automatically expire if a standard discount contract for Dimethylfumarate is concluded at federal or state l...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications